Biogen Inc. (BVMF:BIIB34)

Market Cap	132.77B
Revenue (ttm)	53.65B
Net Income (ttm)	8.57B
Shares Out	n/a
EPS (ttm)	58.49
PE Ratio	15.49
Forward PE	12.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36
Average Volume	54
Open	152.50
Previous Close	155.00
Day's Range	150.30 - 152.50
52-Week Range	110.07 - 169.32
Beta	0.13
RSI	40.60
Earnings Date	Feb 6, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: BIIB34

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD